[Chem. Pharm. Bull.]
[31(5)1698—1701(1983)]

Effects of Oxygenated Lanosterol Analogs on Cholesterol Biosynthesis from Lanosterol¹⁾

YOSHIKO SONODA and YOSHIHIRO SATO*

Kyoritsu College of Pharmacy, Shibakoen 1-chome, Minato-ku, Tokyo 105, Japan

(Received October 6, 1982)

The effects of oxygenated lanosterol derivatives (1—14) on cholesterol biosynthesis from [24-³H]-lanosterol were tested in 10000×*g* supernatant (S₁₀) fraction of rat liver homogenate (RLH). Among the derivatives studied, 7-oxo-24,25-dihydrolanosterol (11) was most active in depressing cholesterol biosynthesis from lanosterol. The inhibitory activities of these derivatives on cholesterol synthesis are discussed in relation to the position and stereochemistry of the oxygen group on the side chain and the sterol nucleus.

Keywords—cholesterol biosynthesis; [24-³H]-lanosterol; oxygenated lanosterol derivative; 7-oxo-24,25-dihydrolanosterol; 24(*R*),25-oxidolanosterol; 24(*S*), 25-oxidolanosterol; rat liver homogenate; inhibition of lanosterol demethylation

Some oxygenated sterols²⁾ are potent inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and lanosterol demethylation in HTC cells. In a previous paper³⁾ we demonstrated that in S₁₀ fraction of rat liver homogenate some lanosterol analogs with different sizes of side chain depressed the rate of cholesterol biosynthesis from lanosterol. This paper describes the effects of fourteen oxygenated lanosterol derivatives on cholesterol synthesis from lanosterol under the same conditions as described previously.³⁾

Inhibitory potency was influenced by the location of the hydroxy function or ketone function on the side chain and by the introduction of an oxygen group into the nucleus. It is of interest that 7-oxo-24,25-dihydrolanosterol (11) was most active in depressing cholesterol biosynthesis from lanosterol.

Materials and Methods

Synthesis of 22*R*- and 22*S*-hydroxylanosterol were reported previously.⁴⁾ 24*R*- and 24*S*-Hydroxy-24,25-dihydrolanosterol,⁵⁾ 24(*R*),25- and 24(*S*),25-oxidolanosterol,⁵⁾ 24-oxo-24,25-dihydrolanosterol,⁶⁾ 26-hydroxylanosterol,⁷⁾ 3β-hydroxylanosta-8,24-dien-26-al,⁷⁾ 7-oxo-24,25-dihydrolanosterol⁸⁾ were prepared as described previously.

7α-Hydroxy-24,25-dihydrolanosterol—This material was synthesized by the method of Shoppee *et al.*⁹⁾ Recrystallization from MeOH gave colorless needles, mp 143—143.5°C. Proton magnetic resonance (PMR) δ (ppm): 0.60 (3H, s, 18-CH₃), 0.81 (3H, s, 4β-CH₃), 0.85 (6H, d, 26 and 27-CH₃, *J*=6.5 Hz), 0.94 (3H, s, 19-CH₃), 1.02 (6H, s, 14 and 4α-CH₃), 3.16—3.40 (1H, m, 3-H), 4.12—4.24 (1H, m, 7-H, *W*_{1/2}=7 Hz). Mass spectrum (MS) *m/e*: 444 (M⁺).

Lanosta-8,24-dien-3α-ol¹⁰⁾ (3-Epilanosterol) (14)—NaBH₄ (0.2 g) was added to a solution of lanosta-8,24-dien-3-one (0.1 g) in MeOH (30 ml) and the reaction mixture was stirred for 1 h at 0°C. Ice-water was added to this reaction mixture and the whole was extracted with CH₂Cl₂, washed with water, dried over sodium sulfate and evaporated to dryness. The residue was column-chromatographed on silica gel (10 g). Elution with benzene gave a solid (6 mg), which was recrystallized from MeOH to give colorless needles of 14, mp 125—125.5°C. PMR δ (ppm): 0.70 (3H, s, 18-CH₃), 0.88 (6H, s, 4 and 14-CH₃), 0.99 (3H, s, 4-CH₃), 1.00 (3H, s, 19-CH₃), 1.60 (3H, s, 26 or 27-CH₃), 1.68 (3H, s, 26 or 27-CH₃), 3.40—3.52 (1H, m, 3-H, *W*_{1/2}=8 Hz), 5.18 (1H, t, 24-H). MS *m/e*: 426 (M⁺).

Further elution with benzene gave a solid (70 mg), which was identified as lanosterol.

Assays for Effects on Cholesterol Biosynthesis from Lanosterol—Experiments to determine the effects of the test compounds on cholesterol biosynthesis from 18 μM [24-³H]-lanosterol were performed at a concentration of 40 μM oxygenated lanosterol derivative in S₁₀ fraction (19.5—20.6 mg protein/ml) of RLH as described previously.³⁾

Chart 1

Results and Discussion

The structures of oxygenated lanosterol derivatives used in this study are shown in Chart 1. Table I shows the effects of fourteen compounds on cholesterol biosynthesis from lanosterol. At the concentration of 40 μM , the compounds with a hydroxy function or ketone function at carbon 26, 25, 24, or 7 of lanosterol or 24,25-dihydrolanosterol, except for the 26-aldehyde compound (**10**), effectively depressed the rate of cholesterol synthesis from lanosterol in S₁₀ fraction of RLH. Among them, 7-oxo-24,25-dihydrolanosterol (**11**) was remarkably active and showed 98% inhibition. On the other hand, 26-aldehyde compound (**10**) showed no activity. 22*R*- and 22*S*-Hydroxylanosterol (**1** and **2**) showed moderate inhibitions (17 and 21%, respectively). In the case of the 7-keto compound (**11**), recovery yield of the substrate was 92%, suggesting that **11** may inhibit 14-demethylation of lanosterol. The relative

inhibitory potencies of the side-chain-hydroxylated sterols were related to the location of the hydroxy function. The order of inhibitory activity was 26-hydroxy lanosterol > 25-hydroxy-24,25-dihydrolanosterol > 24*R*- and 24*S*-hydroxy-24,25-dihydrolanosterol > 22*R*- and 22*S*-hydroxy lanosterol.

TABLE I. Cholesterol Biosynthesis during Incubation of S_{10} Fraction of Rat Liver Homogenate with [24- ^3H]-Lanosterol in the Presence of Oxygenated Lanosterol Derivatives

Compound	Lanosterol Fr. (%)	Cholesterol Fr. (%)	Inhibition (%)
None (control)	24.8	22.8	—
22 <i>R</i> -Hydroxy-L (1)	34.0	19.0	17
22 <i>S</i> -Hydroxy-L (2)	41.2	18.1	21
24 <i>R</i> -Hydroxy-DHL (3)	68.7	12.4	46
24 <i>S</i> -Hydroxy-DHL (4)	62.3	12.9	43
24-Oxo-DHL (5)	62.9	13.0	43
24(<i>R</i>), 25-Oxido-L (6)	50.6	10.3	55
24(<i>S</i>), 25-Oxido-L (7)	52.2	8.9	61
25-Hydroxy-DHL (8) ^{a)}	71.8	8.1	64
26-Hydroxy-L (9)	81.0	5.7	75
26-Aldehyde-L (10) ^{b)}	18.2	26.8	0
7-Oxo-DHL (11)	92.3	0.4	98
7 α -Hydroxy-DHL (12)	60.1	12.0	47
3-Oxo-L (13) ^{c)}	27.6	19.2	16
3-Epi-L (14)	40.6	15.1	34
L (15) ^{a)}	34.5	17.6	23

[24- ^3H]-Lanosterol (90600 dpm; 0.43 $\mu\text{Ci}/\mu\text{mol}$, 18 μM) was incubated with rat liver S_{10} fraction at 37 °C for 3 h. The incubation mixture contained, in a total volume of 5 ml, 4 ml of S_{10} fraction and cofactors. Incubation was started by the addition of the substrate and test compounds as an emulsion (0.1 ml) with Tween 80 (3 mg).¹³⁾ Analytic methods for incubation products and calculation of the percentage inhibition were described previously.¹⁾ Each incubation was carried out in triplicate and the standard deviation of each value listed was less than 5 percent. DHL and L denote 24,25-dihydrolanosterol and lanosterol, respectively.

a) These compounds were tested previously, but were tested again as references; the results differ from those reported previously.¹⁾

b) 26-Aldehyde-L denotes 3 β -hydroxy lanosta-8,24-dien-26-al.

c) 3-Oxo-L denotes lanosta-8,24-dien-3-one.

Some of these oxygenated lanosterol derivatives, 25-hydroxy-24,25-dihydrolanosterol (8)¹¹⁾ and 24(*S*),25-oxidolanosterol (7),¹²⁾ have been reported to be converted efficiently to the corresponding cholesterol derivatives, 25-hydroxycholesterol and 24(*S*),25-epoxycholesterol. The former compound has been shown to exhibit inhibitory activity on incubation with S_{10} fraction of RLH. These results suggest that the oxygenated lanosterol derivatives may be transformed to metabolites which exhibit inhibitory activities.

Further, the transformation of the 3 β -hydroxy group (15) to a 3 α -hydroxy group (14) or 3-keto group (13) caused a small change in the inhibitory effect. The order of inhibitory activity was 3-epilanolsterol > lanosterol > lanosta-8,24-dien-3-one. These results suggest that there is some steric and electrostatic requirement around position C-3 of the A ring for interaction with the enzymes concerned. Our hypothesis is that the 7-keto compound (11) acts by binding to a protein related to lanosterol 14-demethylase.

In summary, it was demonstrated that the inhibitory effects of sterols on cholesterol synthesis are largely related to the position of the oxygen group on the side chain and the sterol skeleton.

Acknowledgement This work was supported in part by a grant from Mishima Kaiun Memorial Foundation.

References and Notes

- 1) Y. Sato, Y. Sonoda, M. Morisaki, and N. Ikekawa, *Chem. Pharm. Bull.*, **31**, 1765 (1983).
- 2) a) P.R. Ortiz de Montellano, J.P. Beck, and G. Ourisson, *Biochem. Biophys. Res. Commun.*, **90**, 897 (1979); b) G.F. Gibbons, C.R. Pullinger, H.W. Chen, W.K. Cavenee, and A.A. Kandustch, *J. Biol. Chem.*, **255**, 395 (1980).
- 3) Y. Sato and Y. Sonoda, *Chem. Pharm. Bull.*, **29**, 2604 (1981).
- 4) Y. Sonoda and Y. Sato, *Chem. Pharm. Bull.*, **31**, 907 (1983).
- 5) R.B. Boar, D.A. Lewis, and J.F. McGhie, *J. Chem. Soc., Perkin Trans. 1*, **1972**, 2231.
- 6) L.H. Briggs, J.P. Bartley, and P.S. Rutledge, *J. Chem. Soc., Perkin Trans. 1*, **1973**, 806.
- 7) F. Nicotra, F. Ronchetti, and G. Russo, *J. Labelled Compounds*, **14**, 541 (1978).
- 8) J.T. Pinkey, B.J. Ralph, J.J.H. Simes, and M. Wootton, *Aust. J. Chem.*, **23**, 2141 (1970).
- 9) C.W. Shoppee, J.C. Coll, and R.E. Lack, *J. Chem. Soc., Perkin Trans. 1*, **1968**, 1581.
- 10) M. Rhohmer, P. Bouvier, and G. Ourisson, *Eur. J. Biochem.*, **112**, 557 (1980).
- 11) J.A. Nelson, S.R. Steckbeck, and T.A. Spencer, *J. Biol. Chem.*, **256**, 1067 (1981).
- 12) S.R. Steckbeck, J.A. Nelson, and T.A. Spencer, *J. Am. Chem. Soc.*, **104**, 893 (1982).
- 13) This surfactant has been used to emulsify sterols in studies on sterol biosynthesis: cf. a) M. Fryberg, A.C. Oehlschlager, and A.M. Unrau, *J. Am. Chem. Soc.*, **95**, 5747 (1973); b) G.F. Gibbons, *Biochem. J.*, **144**, 59 (1974).